This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Clotrimazole with betamethasone

Drugs List

  • clotrimazole 1% and betamethasone 0.05% cream
  • LOTRIDERM cream
  • Therapeutic Indications


    Short term treatment of tinea infections due to; Trichophyton rubrum, T.mentagrophytes, Epidermophyton flocossum and Microsporum canis.

    Treatment of candidiasis due to Candida albicans.



    Treatment of tinea cruris, tinea corporis and candidiasis
    Apply twice daily for 2 weeks.

    Treatment of tinea pedis
    Apply twice daily for 4 weeks.


    See Dosage; Adults.


    Children under 12 years of age
    Not recommended.

    Children aged 12 years or above
    See Dosage; Adults.

    When used to treat children, a single treatment course should not exceed 5 days.


    Children under 12 years old
    Facial rosacea
    Acne vulgaris
    Perioral dermatitis
    Nappy rash
    Bacterial skin infection
    Viral skin infection

    Precautions and Warnings

    Pregnancy - see Pregnancy section.
    Breastfeeding - see Lactation section.

    Discontinue treatment and initiate appropriate therapy if skin irritation or sensitisation occurs.

    Prolonged use on large areas of damaged skin and in skin flexures can result in local and systemic toxicity.

    When used to treat children or facial areas, a single treatment course should not exceed 5 days.

    Long term continuous therapy is not recommended in children of any age.

    Use of occlusive dressings should be avoided.

    Avoid contact with eyes.

    Topical steroids should be used with caution in patients with psoriasis due to the risk of developing generalised pustular psoriasis, rebound relapses following the development of tolerance and local and systemic toxicity as a result of impaired barrier function of skin.

    Pregnancy and Lactation


    Use with caution during pregnancy.

    Avoid application of large quantities or for prolonged periods.

    Animal studies with clotrimazole have shown no teratogenic effects. Foetotoxicity has been observed at high oral doses. Animal studies with corticosteroids have shown adverse effects on foetal development including cleft palate and intra-uterine growth retardation. The potential risk to humans is unknown.

    Schaefer (2007) concludes that topical steroids can be used during pregnancy as long as the treatment time is brief and the area to be covered is not extensive. Whenever possible, the lowest potency of topical steroid should be selected.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use with caution during lactation.

    It is not known whether clotrimazole and betamethasone are excreted in breast milk.

    It is recommended to use the least potent drug on the smallest area of skin possible and to insure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Any excess cream should be removed from the breast before nursing.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Hypersensitivity reactions
    Adrenal suppression
    Exacerbation of infection
    Thinning of skin
    Perioral dermatitis
    Mild depigmentation and vellus hair
    Burning sensation
    Maculopapular rash
    Secondary infections
    Skin peeling
    Skin irritation
    Acne-like eruptions
    Allergic contact dermatitis
    Skin atrophy
    Dry skin
    Maceration of skin


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Reference Sources

    British National Formulary, 63rd Edition (2012) Pharmaceutical Press, London.

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London

    Summary of Product Characteristics: Lotriderm cream. Pliva Pharma Ltd. Revised June 2003

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Betamethasone, Topical. Last revised: July 10, 2012
    Last accessed: August 6, 2012

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Clotrimazole. Last revised: April 03, 2012
    Last accessed: August 6, 2012

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.